New combo therapy before surgery shows promise for tough esophageal cancer
NCT ID NCT06764355
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with locally advanced esophageal cancer. Participants first receive a combination of immunotherapy and chemotherapy, then chemoradiation, followed by surgery. The goal is to see if this sequence can shrink tumors more effectively and improve long-term outcomes. About 50 adults with squamous cell carcinoma of the esophagus are being recruited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, 100229, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- MRI-Guided radiation boosts hopes for rectal cancer patients
- New drug duo aims to wipe out esophageal tumors before surgery
- New trial aims to save rectums in early cancer patients
- Ultrasound may spare breast cancer patients unnecessary surgery
- Could a drug combo let some esophageal cancer patients skip surgery?